Sapporo Clinical Laboratory (TSE:9776) Cyclically Adjusted Revenue per Share: 円2,721.30 (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:9776 Sapporo Clinical Laboratory Inc TSE:9776
43 GF Score
Price 円1,960.00
GF Value 円1,041.47
! 4 Warning Signs
View Full Analysis

What is Sapporo Clinical Laboratory Cyclically Adjusted Revenue per Share?

Sapporo Clinical Laboratory TSE:9776 43 Cyclically Adjusted Revenue per Share is 円2,721.30 as of Sep. 2025. GuruFocus rates TSE:9776 with a GF Score™ of 43/100 and a GF Value™ of 円1,041.47. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sapporo Clinical Laboratory's adjusted revenue per share data for the fiscal year that ended in Mar. 2025 was 円6,433.804. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円2,721.30 for the trailing ten years ended in Mar. 2025.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sapporo Clinical Laboratory was 5.90% per year. The lowest was 3.50% per year. And the median was 4.70% per year.

As of today (2026-08-13), Sapporo Clinical Laboratory's current stock price is 円 1960.00. Sapporo Clinical Laboratory's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Mar. 2025 was 円2,721.30. Sapporo Clinical Laboratory's Cyclically Adjusted PS Ratio of today is 0.72.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sapporo Clinical Laboratory was 0.47. The lowest was 0.28. And the median was 0.38.


Sapporo Clinical Laboratory  (TSE:9776) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sapporo Clinical Laboratory's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1960.00/2721.30
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sapporo Clinical Laboratory was 0.47. The lowest was 0.28. And the median was 0.38.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sapporo Clinical Laboratory Cyclically Adjusted Revenue per Share Related Terms


Sapporo Clinical Laboratory Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Sapporo Clinical Laboratory's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sapporo Clinical Laboratory Cyclically Adjusted Revenue per Share Chart

Sapporo Clinical Laboratory Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,439.85 3,033.96 3,160.27 2,834.88 2,721.30

Sapporo Clinical Laboratory Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,466.02 2,834.88 0.00 2,721.30 0.00

Sapporo Clinical Laboratory Cyclically Adjusted Revenue per Share Competitor Comparison

For the Pharmaceutical Retailers subindustry, Sapporo Clinical Laboratory's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sapporo Clinical Laboratory Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Sapporo Clinical Laboratory's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sapporo Clinical Laboratory's Cyclically Adjusted PS Ratio falls into.


TSE:9776
43GF Score
Sapporo Clinical Laboratory Inc TSE:9776
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sapporo Clinical Laboratory Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sapporo Clinical Laboratory's adjusted Revenue per Share data for the fiscal year that ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=6433.804/111.1000*111.1000
=6,433.804

Current CPI (Mar. 2025) = 111.1000.

Sapporo Clinical Laboratory Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201603 5,038.301 97.900 5,717.622
201703 4,902.327 98.100 5,551.973
201803 5,020.115 99.200 5,622.326
201903 4,971.047 99.700 5,539.452
202003 5,158.949 100.300 5,714.449
202103 5,113.218 99.900 5,686.472
202203 5,610.568 101.100 6,165.520
202303 6,037.100 104.400 6,424.538
202403 5,908.832 107.200 6,123.799
202503 6,433.804 111.100 6,433.804

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円2,721.30 mean?
Sapporo Clinical Laboratory (TSE:9776) has a Cyclically Adjusted Revenue per Share of 円2,721.30 as of Sep. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sapporo Clinical Laboratory and its competitors.
Is Sapporo Clinical Laboratory's Cyclically Adjusted Revenue per Share too high?
Sapporo Clinical Laboratory's current Cyclically Adjusted Revenue per Share is 円2,721.30. Overall, Sapporo Clinical Laboratory has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Sapporo Clinical Laboratory's Cyclically Adjusted Revenue per Share compare to competitors?
Sapporo Clinical Laboratory's Cyclically Adjusted Revenue per Share of 円2,721.30 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Healthcare Providers & Services company?
A good Cyclically Adjusted Revenue per Share depends on the Healthcare Providers & Services industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sapporo Clinical Laboratory and its competitors. Sapporo Clinical Laboratory's current Cyclically Adjusted Revenue per Share is 円2,721.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sapporo Clinical Laboratory stock overvalued right now?
Sapporo Clinical Laboratory (TSE:9776) has a current Cyclically Adjusted Revenue per Share of 円2,721.30. The stock's GF Value™ is 円1,041.47, compared to a current price of 円1,960.00 — trading 88.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円2,721.30. Sapporo Clinical Laboratory's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Sapporo Clinical Laboratory (TSE:9776), the current Cyclically Adjusted Revenue per Share is 円2,721.30 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sapporo Clinical Laboratory (TSE:9776) Overvalued in 2026?

Based on GuruFocus' analysis, Sapporo Clinical Laboratory stock appears to be overvalued. The current stock price of 円1,960.00 is trading 88.2% above its estimated GF Value™ of 円1,041.47.

Key valuation signals for TSE:9776:

  • Cyclically Adjusted Revenue per Share: 円2,721.30
  • GF Value™: 円1,041.47 vs. price of 円1,960.00 (88.2% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the TSE:9776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sapporo Clinical Laboratory Business Description

Address 18-9-1 Nishi Kita-Gojo, Chuo-ku Sapporo, Hokkaido, Sapporo, JPN, 060 0005
Sapporo Clinical Laboratory Inc. is a Japan based company engaged in offering clinical testing services. Its portfolio of services covers clinical examination, pathological examination, dispensing pharmacy, food hygiene environmental test, and radiation management. It is also engaged in the development of an integrated system for clinical testing.
43GF Score

Get the complete analysis for TSE:9776

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,960.00
Price
円1,041.47
GF Value